难治疗病原体所致感染临床实践中的新型抗菌药物选择：公共卫生的全球机遇
New Antimicrobial Options in the Clinical Practice of Infections Caused by Difficult-to-Treat Pathogens: A Global Opportunity for Public Health.
作者信息
Principe Luigi
机构信息
Clinical Pathology and Microbiology Unit, "S. Giovanni di Dio" Hospital, 88900 Crotone, Italy.
出版信息
Antibiotics (Basel). 2022 May 31;11(6):740. doi: 10.3390/antibiotics11060740.
Abstract
Antimicrobial resistance (AMR) is a serious cause of concern for public health [...].
摘要
抗菌药物耐药性（AMR）是公共卫生领域一个严重的关切问题[……]。
相似文献
1
New Antimicrobial Options in the Clinical Practice of Infections Caused by Difficult-to-Treat Pathogens: A Global Opportunity for Public Health.难治疗病原体所致感染临床实践中的新型抗菌药物选择：公共卫生的全球机遇
Antibiotics (Basel). 2022 May 31;11(6):740. doi: 10.3390/antibiotics11060740.
2
Antimicrobial Resistance: A Growing Serious Threat for Global Public Health.抗菌药物耐药性：对全球公共卫生日益严重的威胁。
Healthcare (Basel). 2023 Jul 5;11(13):1946. doi: 10.3390/healthcare11131946.
3
Current state of the art in rapid diagnostics for antimicrobial resistance.当前抗菌药物耐药性快速诊断技术的现状。
Lab Chip. 2020 Aug 7;20(15):2607-2625. doi: 10.1039/d0lc00034e. Epub 2020 Jul 9.
4
Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now?撒哈拉以南非洲地区的抗菌药物耐药率及监测：我们目前的状况如何？
Infect Drug Resist. 2022 Jul 7;15:3589-3609. doi: 10.2147/IDR.S342753. eCollection 2022.
5
Pandemics, public health emergencies and antimicrobial resistance - putting the threat in an epidemiologic and risk analysis context.大流行、突发公共卫生事件与抗菌药物耐药性——将威胁置于流行病学和风险分析背景下
Arch Public Health. 2017 Sep 14;75:54. doi: 10.1186/s13690-017-0223-7. eCollection 2017.
6
Measuring and mapping the global burden of antimicrobial resistance.测量和绘制全球抗菌药物耐药性负担图。
BMC Med. 2018 Jun 4;16(1):78. doi: 10.1186/s12916-018-1073-z.
7
Meta-Analysis for the Global Prevalence of Foodborne Pathogens Exhibiting Antibiotic Resistance and Biofilm Formation.全球食源性病原体抗生素耐药性及生物膜形成流行率的Meta分析
Front Microbiol. 2022 Jun 14;13:906490. doi: 10.3389/fmicb.2022.906490. eCollection 2022.
8
The Silent Threat: Antimicrobial-Resistant Pathogens in Food-Producing Animals and Their Impact on Public Health.无声的威胁：食用动物中的抗菌药物耐药病原体及其对公众健康的影响。
Microorganisms. 2023 Aug 22;11(9):2127. doi: 10.3390/microorganisms11092127.
9
Existing terminology related to antimicrobial resistance fails to evoke risk perceptions and be remembered.现有的与抗菌药物耐药性相关的术语无法唤起风险认知，也难以被记住。
Commun Med (Lond). 2023 Oct 25;3(1):149. doi: 10.1038/s43856-023-00379-6.
10
Microbial Resistance Movements: An Overview of Global Public Health Threats Posed by Antimicrobial Resistance, and How Best to Counter.微生物耐药动态：对抗菌药物耐药性所构成的全球公共卫生威胁的概述以及最佳应对方法。
Front Public Health. 2020 Nov 4;8:535668. doi: 10.3389/fpubh.2020.535668. eCollection 2020.
引用本文的文献
1
Exploration of the Antibacterial and Anti-Inflammatory Activity of a Novel Antimicrobial Peptide Brevinin-1BW.新型抗菌肽 Brevinin-1BW 的抗菌和抗炎活性研究
Molecules. 2024 Mar 29;29(7):1534. doi: 10.3390/molecules29071534.
本文引用的文献
1
Antimicrobial Susceptibility, Virulence, and Genomic Features of a Hypervirulent Serotype K2, ST65 Causing Meningitis in Italy.在意大利引起脑膜炎的高毒力K2血清型、ST65的抗菌药敏性、毒力及基因组特征
Antibiotics (Basel). 2022 Feb 17;11(2):261. doi: 10.3390/antibiotics11020261.
2
XDR- Outside the ICU: Is There Still Place for Colistin?广泛耐药菌——重症监护病房之外：黏菌素是否仍有一席之地？
Antibiotics (Basel). 2022 Feb 1;11(2):193. doi: 10.3390/antibiotics11020193.
3
Antimicrobial Activity of Aztreonam in Combination with Old and New β-Lactamase Inhibitors against MBL and ESBL Co-Producing Gram-Negative Clinical Isolates: Possible Options for the Treatment of Complicated Infections.氨曲南与新旧β-内酰胺酶抑制剂联合对产金属β-内酰胺酶和超广谱β-内酰胺酶的革兰阴性临床分离株的抗菌活性：治疗复杂感染的可能选择
Antibiotics (Basel). 2021 Nov 3;10(11):1341. doi: 10.3390/antibiotics10111341.
4
In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against Strains Recovered from Clinical Samples.铁载体头孢菌素头孢地尔对临床样本分离菌株的体外抗菌活性
Antibiotics (Basel). 2021 Oct 27;10(11):1309. doi: 10.3390/antibiotics10111309.
5
Heteroaryl-Ethylenes as New Lead Compounds in the Fight against High Priority Bacterial Strains.杂芳基乙烯作为对抗高优先级细菌菌株的新型先导化合物。
Antibiotics (Basel). 2021 Aug 25;10(9):1034. doi: 10.3390/antibiotics10091034.
6
Direct Testing for KPC-Mediated Carbapenem Resistance from Blood Samples Using a T2 Magnetic Resonance Based Assay.使用基于T2磁共振的检测方法直接检测血液样本中KPC介导的碳青霉烯类耐药性
Antibiotics (Basel). 2021 Aug 6;10(8):950. doi: 10.3390/antibiotics10080950.
7
Whole-Genome Sequencing Investigation of a Large Nosocomial Outbreak Caused by ST131 H30Rx KPC-Producing in Italy.意大利一起由产KPC的ST131 H30Rx引起的大型医院感染暴发的全基因组测序调查
Antibiotics (Basel). 2021 Jun 15;10(6):718. doi: 10.3390/antibiotics10060718.
8
Synergistic Meropenem/Vaborbactam Plus Fosfomycin Treatment of KPC Producing Septic Thrombosis Unresponsive to Ceftazidime/Avibactam: From the Bench to the Bedside.美罗培南/瓦博巴坦与磷霉素联合治疗对头孢他啶/阿维巴坦无反应的产KPC败血症性血栓形成：从实验室到临床
Antibiotics (Basel). 2021 Jun 27;10(7):781. doi: 10.3390/antibiotics10070781.
9
Epidemiology of Meropenem/Vaborbactam Resistance in KPC-Producing Causing Bloodstream Infections in Northern Italy, 2018.2018年意大利北部产KPC菌引起血流感染的美罗培南/巴他唑巴坦耐药性流行病学
Antibiotics (Basel). 2021 May 6;10(5):536. doi: 10.3390/antibiotics10050536.
10
Ceftobiprole Perspective: Current and Potential Future Indications.头孢比普展望：当前及未来潜在适应症
Antibiotics (Basel). 2021 Feb 8;10(2):170. doi: 10.3390/antibiotics10020170.
Zotero 插件